Flu myths

Dispelling the myths associated with live attenuated influenza vaccine

Pritish K. Tosh, Thomas G. Boyce, Gregory A. Poland

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Live attenuated influenza vaccine (LAIV), commercially available since 2003, has not gained widespread acceptance among prescribes. This underuse can be traced to several misperceptions and fears regarding LAIV. This review examines both the facts (safety, immunogenicity, and effectiveness) and the most pervasive myths about LAIV. Live attenuated influenza vaccine is a safe, highly immunogenic, and effective vaccine. It is well tolerated; only mild and transient upper respiratory infection symptoms occur with LAIV vs placebo, even in higher-risk patients with asthma or the early stages of human immunodeficiency virus. It is immunogenic, especially in induction of mucosal immunity. In certain populations, LAIV is as effective as, and in some cases more effective than, inactivated influenza in preventing influenza infection. It appears to be more effective in preventing influenza infection than trivalent inactivated influenza vaccine when the vaccine virus strain does not closely match that of the circulating wild-type virus. Many myths and misperceptions about the vaccine exist, foremost among them the myth of genetic reversion. Independent mutation in 4 gene segments would be required for reversion of the vaccine strain of influenza virus to a wild type, an unlikely and as yet unobserved event. Although shedding of vaccine virus is common, transmission of vaccine virus has been documented only in a single person, who remained asymptomatic. In the age groups for which it is indicated, LAIV is a safe and effective vaccine to prevent influenza infection.

Original languageEnglish (US)
Pages (from-to)77-84
Number of pages8
JournalMayo Clinic Proceedings
Volume83
Issue number1
DOIs
StatePublished - 2008

Fingerprint

Attenuated Vaccines
Influenza Vaccines
Vaccines
Human Influenza
Viruses
Infection
Virus Shedding
Mucosal Immunity
Inactivated Vaccines
Respiratory Tract Infections
Fear
Asthma
Age Groups
Placebos
HIV
Safety
Mutation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Flu myths : Dispelling the myths associated with live attenuated influenza vaccine. / Tosh, Pritish K.; Boyce, Thomas G.; Poland, Gregory A.

In: Mayo Clinic Proceedings, Vol. 83, No. 1, 2008, p. 77-84.

Research output: Contribution to journalArticle

Tosh, Pritish K. ; Boyce, Thomas G. ; Poland, Gregory A. / Flu myths : Dispelling the myths associated with live attenuated influenza vaccine. In: Mayo Clinic Proceedings. 2008 ; Vol. 83, No. 1. pp. 77-84.
@article{ceb9820adcd6428db40cc7544c0fc13e,
title = "Flu myths: Dispelling the myths associated with live attenuated influenza vaccine",
abstract = "Live attenuated influenza vaccine (LAIV), commercially available since 2003, has not gained widespread acceptance among prescribes. This underuse can be traced to several misperceptions and fears regarding LAIV. This review examines both the facts (safety, immunogenicity, and effectiveness) and the most pervasive myths about LAIV. Live attenuated influenza vaccine is a safe, highly immunogenic, and effective vaccine. It is well tolerated; only mild and transient upper respiratory infection symptoms occur with LAIV vs placebo, even in higher-risk patients with asthma or the early stages of human immunodeficiency virus. It is immunogenic, especially in induction of mucosal immunity. In certain populations, LAIV is as effective as, and in some cases more effective than, inactivated influenza in preventing influenza infection. It appears to be more effective in preventing influenza infection than trivalent inactivated influenza vaccine when the vaccine virus strain does not closely match that of the circulating wild-type virus. Many myths and misperceptions about the vaccine exist, foremost among them the myth of genetic reversion. Independent mutation in 4 gene segments would be required for reversion of the vaccine strain of influenza virus to a wild type, an unlikely and as yet unobserved event. Although shedding of vaccine virus is common, transmission of vaccine virus has been documented only in a single person, who remained asymptomatic. In the age groups for which it is indicated, LAIV is a safe and effective vaccine to prevent influenza infection.",
author = "Tosh, {Pritish K.} and Boyce, {Thomas G.} and Poland, {Gregory A.}",
year = "2008",
doi = "10.4065/83.1.77",
language = "English (US)",
volume = "83",
pages = "77--84",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "1",

}

TY - JOUR

T1 - Flu myths

T2 - Dispelling the myths associated with live attenuated influenza vaccine

AU - Tosh, Pritish K.

AU - Boyce, Thomas G.

AU - Poland, Gregory A.

PY - 2008

Y1 - 2008

N2 - Live attenuated influenza vaccine (LAIV), commercially available since 2003, has not gained widespread acceptance among prescribes. This underuse can be traced to several misperceptions and fears regarding LAIV. This review examines both the facts (safety, immunogenicity, and effectiveness) and the most pervasive myths about LAIV. Live attenuated influenza vaccine is a safe, highly immunogenic, and effective vaccine. It is well tolerated; only mild and transient upper respiratory infection symptoms occur with LAIV vs placebo, even in higher-risk patients with asthma or the early stages of human immunodeficiency virus. It is immunogenic, especially in induction of mucosal immunity. In certain populations, LAIV is as effective as, and in some cases more effective than, inactivated influenza in preventing influenza infection. It appears to be more effective in preventing influenza infection than trivalent inactivated influenza vaccine when the vaccine virus strain does not closely match that of the circulating wild-type virus. Many myths and misperceptions about the vaccine exist, foremost among them the myth of genetic reversion. Independent mutation in 4 gene segments would be required for reversion of the vaccine strain of influenza virus to a wild type, an unlikely and as yet unobserved event. Although shedding of vaccine virus is common, transmission of vaccine virus has been documented only in a single person, who remained asymptomatic. In the age groups for which it is indicated, LAIV is a safe and effective vaccine to prevent influenza infection.

AB - Live attenuated influenza vaccine (LAIV), commercially available since 2003, has not gained widespread acceptance among prescribes. This underuse can be traced to several misperceptions and fears regarding LAIV. This review examines both the facts (safety, immunogenicity, and effectiveness) and the most pervasive myths about LAIV. Live attenuated influenza vaccine is a safe, highly immunogenic, and effective vaccine. It is well tolerated; only mild and transient upper respiratory infection symptoms occur with LAIV vs placebo, even in higher-risk patients with asthma or the early stages of human immunodeficiency virus. It is immunogenic, especially in induction of mucosal immunity. In certain populations, LAIV is as effective as, and in some cases more effective than, inactivated influenza in preventing influenza infection. It appears to be more effective in preventing influenza infection than trivalent inactivated influenza vaccine when the vaccine virus strain does not closely match that of the circulating wild-type virus. Many myths and misperceptions about the vaccine exist, foremost among them the myth of genetic reversion. Independent mutation in 4 gene segments would be required for reversion of the vaccine strain of influenza virus to a wild type, an unlikely and as yet unobserved event. Although shedding of vaccine virus is common, transmission of vaccine virus has been documented only in a single person, who remained asymptomatic. In the age groups for which it is indicated, LAIV is a safe and effective vaccine to prevent influenza infection.

UR - http://www.scopus.com/inward/record.url?scp=37549045609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549045609&partnerID=8YFLogxK

U2 - 10.4065/83.1.77

DO - 10.4065/83.1.77

M3 - Article

VL - 83

SP - 77

EP - 84

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 1

ER -